Glycan Covalent Targeting Chimera‐Based T‐Cell Glycoengineering for Boosting Immunotherapy
Chemistry – A European Journal · 2025
DOI: 10.1002/chem.202500364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, 2025. Verfasst von Yichun Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023, Chi…. Hauptthemen laut MEDLINE: Polysaccharides, T-Lymphocytes, Immunotherapy, Receptors, Chimeric Antigen. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T‐cell therapy is one of the most effective approaches in cancer immunotherapy. However, shortcomings such as loss of target antigens and poor infiltration remain in the treatment of solid tumors. Herein, we propose an approach to glycoengineer T cells based on glycan covalent targeting chimera (gcTAC), to enhance immunotherapy by modulating the glycan recognition behavior of T cells. We select hydrazide‐modified phenylboronic acid (PBA) as gcTAC. The hydrazide group can covalently couple with the aldehyde group generated by the oxidation of galactose/ N ‐acetylgalactosamine on the surface of T cells, while the PBA at the other end can specifically bind to sialic acids (Sia) of tumor cells, thereby enhancing the killing effect of T cells. At the same time, T cells covalently bound to tumor cells surfaces act as a blockade of Sia sites, which can disrupt the recognition between Siglec on natural killer (NK) cells and Sia on tumor cells, further enhancing the immune‐killing effect of combined T–NK cell therapy. Our approach represents a novel concept to promote immune killing through cascading interventions in T–tumor and tumor–NK intercellular glycan recognition, thus providing a solution to the problem of immune escape in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023, China.
- State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023, China.
- Affiliated Jinhua Hospital, Zhejiang University School of Medicine, No. 365 East Renmin Road, Jinhua, 321000, China.
- Chemistry and Biomedicine Innovation Center (ChemBIC), ChemBioMed Interdisciplinary Research Center, Nanjing University, Nanjing, 210023, China.
ORCID-Profile: Lin Ding
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Yan, X., Lu, D., Wang, H., Li, K., Chen, L., Wang, L., Cheng, S., Wang, G., Wang, R., Xue, Y., Li, Y., Xie, R., & Ding, L. (2025). Glycan Covalent Targeting Chimera‐Based T‐Cell Glycoengineering for Boosting Immunotherapy. Chemistry – A European Journal. https://doi.org/10.1002/chem.202500364
Vancouver
Wang Y, Yan X, Lu D, Wang H, Li K, Chen L, et al. Glycan Covalent Targeting Chimera‐Based T‐Cell Glycoengineering for Boosting Immunotherapy. Chemistry – A European Journal. 2025. doi:10.1002/chem.202500364
BibTeX
@article{Wang2025,
author = {Wang, Yichun and Yan, Xiaomin and Lu, Di and Wang, Haiqi and Li, Ke and Chen, Liusheng and Wang, Lan and Cheng, Songtao and Wang, Guyu and Wang, Ruiyuan and Xue, Yadong and Li, Yiran and Xie, Ran and Ding, Lin},
title = {Glycan Covalent Targeting Chimera‐Based T‐Cell Glycoengineering for Boosting Immunotherapy},
journal = {Chemistry – A European Journal},
year = {2025},
doi = {10.1002/chem.202500364}
}
EUVIMED